<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03485495</url>
  </required_header>
  <id_info>
    <org_study_id>MMH-DV-010</org_study_id>
    <nct_id>NCT03485495</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Efficacy and Safety of Divaza for Adjustment of Oxidative Disorders in Patients With Cerebral Atherosclerosis</brief_title>
  <official_title>Multicenter Double-blind Placebo-controlled Randomized Parallel-group Clinical Study of Efficacy and Safety of Divaza for Adjustment of Oxidative Disorders in Patients With Cerebral Atherosclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Materia Medica Holding</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Materia Medica Holding</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to obtain additional data on efficacy and safety of Divaza for&#xD;
      adjustment of oxidative disorders in patients with cerebral atherosclerosis.&#xD;
&#xD;
      It is assumed that the inclusion of the drug Divaza in the basic therapy will help reduce the&#xD;
      severity of cognitive disorders, other clinical symptoms of cerebral atherosclerosis, reduce&#xD;
      the impact of the disease on the quality of life of the patient.&#xD;
&#xD;
      Participate in the study may be patients with a diagnosis of &quot;cerebral atherosclerosis&quot;,&#xD;
      which, against the backdrop of basic therapy with constant doses of drugs (within the last 4&#xD;
      weeks), to achieve a stable course of cerebral atherosclerosis, cognitive disorders without&#xD;
      significant disability are detected.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design - a multicenter randomized double-blind placebo-controlled parallel-group clinical&#xD;
      trial.&#xD;
&#xD;
      The study will enroll the patients of either gender aged 40-75 years old inclusively with&#xD;
      verified atherosclerotic cerebrovascular lesions (ICD-10 code - &quot;Cerebral atherosclerosis&quot;&#xD;
      [I67.2]), with cognitive disorders (МоСА&lt;26), without relevant incapacity (mRs≤1).&#xD;
&#xD;
      At screening visit (Visit 1, from day - 5 to day 0), after signing patient information sheet&#xD;
      (informed consent form) for participation in the clinical study the patient's complaints and&#xD;
      medical history will be collected and objective examination will be carried out. The&#xD;
      investigator will assess intensity of cognitive disorders using MoCA, extent of functional&#xD;
      capacity using mRs .&#xD;
&#xD;
      If the patient meets inclusion criteria and has no exclusion criteria at Visit 2 (Day 0)&#xD;
      he/she will be randomized to one of two groups: group 1 will receive Divaza at 2 tablets 3&#xD;
      times a day; group 2 - placebo using study drug scheme.&#xD;
&#xD;
      Laboratory examination will be performed.&#xD;
&#xD;
        1. oxidant and antioxidant systems (Fe2+-induced chemoluminescence method, ELISA) defining:&#xD;
           1.1. level of preformed LP products, predominantly lipid hydroperoxides; 1.2. low and&#xD;
           very low density lipoprotein resistance to LP; 1.3. lipoprotein potential for oxidation;&#xD;
           1.4. serum NO product concentration (Griess reaction).&#xD;
&#xD;
        2. compensatory potential of endothelium and its ability for adequate regulation of&#xD;
           vascular tone with : 2.1. determination of platelet aggregation with bandage sign; 2.2.&#xD;
           MAH duplex scanning. Procedures of Visit 2 may be performed on day of Visit 1 if general&#xD;
           rules for blood collection are met, at that previously performed procedures will not be&#xD;
           repeated.&#xD;
&#xD;
      The first administration of Divaza or Placebo will be performed at Visit 2 at medical site in&#xD;
      the investigator's presence. The patient monitoring and therapy will last for 12 weeks during&#xD;
      which 3 additional visits will be made.&#xD;
&#xD;
      At Visit 3 (Week 4±5 days) the investigator will collect the complaints, perform objective&#xD;
      examination, evaluate intensity of cognitive disorders (MoCA). The investigator will monitor&#xD;
      the prescribed, basic and concomitant therapy, evaluate therapeutic safety.&#xD;
&#xD;
      At Visit 4 (Week 8±5 days) the investigator will make a phone call to the patient to evaluate&#xD;
      safety of the treatment.&#xD;
&#xD;
      At the final Visit 5 (Weeks 12±5 days) the investigator will evaluate intensity of cognitive&#xD;
      disorders (MoCA). Laboratory examination of oxidant and antioxidant systems, compensatory&#xD;
      potential of endothelium and its potential for adequate vascular tone regulation. The&#xD;
      investigator will monitor the prescribe, basic and concomitant therapy, evaluate therapeutic&#xD;
      safety and treatment compliance.&#xD;
&#xD;
      During the study basic, concomitant therapy will be allowed except for the products indicated&#xD;
      in the section &quot;Prohibited concomitant therapy&quot;.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 12, 2018</start_date>
  <completion_date type="Actual">April 11, 2019</completion_date>
  <primary_completion_date type="Actual">April 11, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Mean Value of Lipoprotein Resistance to LPO.</measure>
    <time_frame>12 weeks of the observation period.</time_frame>
    <description>Based on laboratory evaluation. Change in the mean resistance of lipoprotein (LP) to lipid peroxidation (LPO) after 12-week therapy versus baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Improved Cognitive Function.</measure>
    <time_frame>12 weeks of the observation period.</time_frame>
    <description>MoCA (Montreal Cognitive Assessment) score +1 and over after 12-week therapy versus baseline. Minimum score is 0, maximum score is 30. Higher values represent a better outcome.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Mean Level of Preformed LP Products (Mainly Lipid Hydroperoxides).</measure>
    <time_frame>12 weeks of the observation period</time_frame>
    <description>Based on laboratory evaluation. Change in mean level of preformed LP products, predominantly lipid hydroperoxides after 12-week therapy versus baseline.&#xD;
The following kinetic parameters of chemiluminescence were measured: rapid chemiluminescence flare amplitude reflecting the stationary level of lipid hydroperoxides.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Mean Value of Lipoprotein Ability for Oxidation.</measure>
    <time_frame>12 weeks of the observation period.</time_frame>
    <description>Based on laboratory evaluation. Change in mean value of lipoprotein ability for oxidation after 12-week therapy versus baseline.&#xD;
For plasma, draw blood into an EDTA tube and gently invert the tube 8 to 10 times to mix the anticoagulant. Centrifuge the tube, remove the stopper and draw off approximately 2/3 of the upper plasma layer into a labeled transfer tube using a transfer pipet bulb. Plasma must be separated from cells within 45 minutes of venipuncture. Measurement of oxidized LDL (oxLDL) has been incorporated into clinical practice in the diagnosis and treatment of lipid disorders (such as diabetes mellitus), atherosclerosis, and various liver and renal diseases, especially as it pertains to the evaluation of oxidative stress. Oxidized LDL-particles are considered to be an important driving factor in the pathophysiology of atherosclerosis and oxLDL measurement has been used to test the efficacy of CVD drugs (eg, statins) to reduce oxidative stress.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Mean Value of NO Products Serum Concentration.</measure>
    <time_frame>12 weeks of the observation period.</time_frame>
    <description>Based on laboratory evaluation. Change in the mean concentration of nitrites and nitrates in serum after 12-week therapy versus baseline. Griess Reaction assay.&#xD;
In the Griess reaction, first reported by Johann Peter Griess in 1879 as a method of analysis of nitrite (NO2-), nitrite reacts under acidic conditions with sulfanilic acid (HO3SC6H4NH2) to form a diazonium cation (HO3SC6H4-Ntriple bondN+) which subsequently couples to the aromatic amine 1-naphthylamine (C10H7NH2) to produce a red-violet coloured (λmax ≈ 540 nm), water-soluble azo dye (HO3SC6H4-Ndouble bondN-C10H6NH2).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Mean Value of Platelet Aggregation.</measure>
    <time_frame>12 weeks of the observation period.</time_frame>
    <description>Based on laboratory evaluation. Change in mean platelet aggregation after 12-week therapy versus baseline.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Cerebral Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Divaza</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablet for oral use. Two tablets per intake 3 times a day (approximately at the same time), outside of meal (between meals or 15 minutes before eating or drinking). The tablets should be held in mouth until completely dissolved.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tablet for oral use. Two tablets per intake 3 times a day (approximately at the same time), outside of meal (between meals or 15 minutes before eating or drinking). The tablets should be held in mouth until completely dissolved.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Divaza</intervention_name>
    <description>Oral administration.</description>
    <arm_group_label>Divaza</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients of both genders aged 40-75 years old inclusive.&#xD;
&#xD;
          2. Diagnosis of cerebral atherosclerosis verified by all three signs:&#xD;
&#xD;
               -  underlying vascular disease (atherosclerosis and/or hypertension) and focal&#xD;
                  neurological symptoms combined with cerebral symptoms (headache, dizziness,&#xD;
                  tinnitus, impaired memory, working capacity);&#xD;
&#xD;
               -  ultrasound signs of atherosclerotic cerebrovascular lesions (according to MAH&#xD;
                  duplex scanning within 6 months preceding the patient enrollment into the study);&#xD;
&#xD;
               -  signs of morphological changes in the brain based on neuroimaging (CT/MRI 1.0-1.5&#xD;
                  T) (subcortical and periventricular leukoaraiosis and/or focal changes in grey&#xD;
                  matter and white matter in the form of postischemic cysts and/or lacunar strokes&#xD;
                  and/or diffuse atrophic changes in the form of dilated cardiovascular system or&#xD;
                  subarachnoidal spaces).&#xD;
&#xD;
          3. Cognitive disorders (MoCa &lt;26).&#xD;
&#xD;
          4. Patients with unchanged dose and combination of basic therapy of cerebral&#xD;
             atherosclerosis and hypertension during the previous month.&#xD;
&#xD;
          5. Patients who gave their consent to use reliable contraception during the study.&#xD;
&#xD;
          6. Availability of signed patient information sheet and informed consent form for&#xD;
             participation in the clinical trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of subarachnoidal/parenchymatous/ventricular hemorrhage, cerebral tumour or&#xD;
             another disease resulting in neurological disorders.&#xD;
&#xD;
          2. Ischemic-type stroke or any other acute cerebrovascular accident less than 6 months&#xD;
             prior to the study with Modified Rankin Scale (mRs) &gt; 1 .&#xD;
&#xD;
          3. Cardiac sources of high risk or medium risk embolism (TOAST criteria).&#xD;
&#xD;
          4. Signs of acute or exacerbated chronic infectious diseases at or less than 2 weeks&#xD;
             prior to screening.&#xD;
&#xD;
          5. History of CNS diseases including:&#xD;
&#xD;
               -  Inflammatory CNS diseases (G00-G09)&#xD;
&#xD;
               -  Systemic Atrophies Primarily Affecting the CNS (G10-G13)&#xD;
&#xD;
               -  Other degenerative diseases of the nervous system (G30-G32)&#xD;
&#xD;
               -  Demyelinating diseases of the CNS (G35-G37).&#xD;
&#xD;
          6. Dementia (F00-F03).&#xD;
&#xD;
          7. Previously diagnosed cardiovascular diseases with functional class III or IV&#xD;
             (according to New York Heart Association, 1964).&#xD;
&#xD;
          8. Hypothyroidism, diabetes mellitus and other somatic diseases at decompensation stage.&#xD;
&#xD;
          9. Uncontrollable hypertension: SBP &gt; 180 mm Hg and/or DBP &gt; 110 mm Hg.&#xD;
&#xD;
         10. Diseases of lower limb veins (lower limb varicose veins, deep venous thrombosis, etc.)&#xD;
             at decompensation stage.&#xD;
&#xD;
         11. Any other severe concomitant pathology which, according to the investigator, may&#xD;
             interfere with the patient's participation in the study.&#xD;
&#xD;
         12. History/suspicion of oncology of any location (except for benign neoplasms).&#xD;
&#xD;
         13. Allergy/intolerance of any component of the drug products used in the therapy.&#xD;
&#xD;
         14. Hereditary lactose intolerance.&#xD;
&#xD;
         15. Malabsorption syndrome, including congenital or acquired lactase deficiency (or any&#xD;
             other disaccharidase deficiency) and galactosemia.&#xD;
&#xD;
         16. Pregnancy, breast-feeding.&#xD;
&#xD;
         17. History of treatment non-compliance, psychiatric disorders, alcoholism or drug abuse&#xD;
             which, according to the investigator, may interfere with the study procedures.&#xD;
&#xD;
         18. Use of any medicine indicated in the section &quot;Prohibited concomitant treatment&quot; within&#xD;
             1 month prior to enrollment.&#xD;
&#xD;
         19. Participation in other clinical trials in the previous 3 months.&#xD;
&#xD;
         20. Patients who are related to any of the on-site research personnel directly involved in&#xD;
             the study or are an immediate relative of the study investigator, or has another&#xD;
             conflict of interests. 'Immediate relative' means husband, wife, parent, son,&#xD;
             daughter, brother, or sister (regardless of whether they are natural or adopted).&#xD;
&#xD;
         21. Patients who work for OOO &quot;NPF &quot;MATERIA MEDICA HOLDING&quot; (i.e. the company's employees,&#xD;
             temporary contract workers, appointed officials responsible for carrying out the&#xD;
             research or immediate relatives of the aforementioned).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Limited Liability Company &quot;Family policlinic no. 4&quot;</name>
      <address>
        <city>Korolev</city>
        <zip>141060</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow City Clinical Hospital after V.M. Buyanov</name>
      <address>
        <city>Moscow</city>
        <zip>115516</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Institution of Healthcare of the City of Moscow City Clinical Hospital No. 1 named after. N.I. Pirogov Moscow Department of Health</name>
      <address>
        <city>Moscow</city>
        <zip>119049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Institution Federal Research and Clinical Center of Physical-Chemical Medicine Federal Medical Biological Agency</name>
      <address>
        <city>Moscow</city>
        <zip>119435</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>119992</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budget Scientific Institution &quot;Scientific Center of Neurology&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>1253678</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The state budgetary health care institution of the Vladimir region &quot;Regional Clinical Hospital&quot;</name>
      <address>
        <city>Vladimir</city>
        <zip>600023</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Educational Institution of Higher Education &quot;Yaroslavl State Medical University&quot; of the Ministry of Healthcare of the Russian Federation</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Institution of Health of the Yaroslavl Region Clinical Hospital No. 8</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150030</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State budgetary institution of health care of the Yaroslavl region &quot;Regional Clinical Hospital&quot;</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 26, 2018</study_first_submitted>
  <study_first_submitted_qc>March 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2018</study_first_posted>
  <results_first_submitted>April 29, 2021</results_first_submitted>
  <results_first_submitted_qc>August 25, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 26, 2021</results_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Arteriosclerosis</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 5, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/95/NCT03485495/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Divaza</title>
          <description>Tablet for oral use. Two tablets per intake 3 times a day (approximately at the same time), outside of meal (between meals or 15 minutes before eating or drinking). The tablets should be held in mouth until completely dissolved.&#xD;
Divaza: Oral administration.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Tablet for oral use. Two tablets per intake 3 times a day (approximately at the same time), outside of meal (between meals or 15 minutes before eating or drinking). The tablets should be held in mouth until completely dissolved.&#xD;
Placebo: Oral administration.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Non-compliance with inclusion criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Divaza</title>
          <description>Tablet for oral use. Two tablets per intake 3 times a day (approximately at the same time), outside of meal (between meals or 15 minutes before eating or drinking). The tablets should be held in mouth until completely dissolved.&#xD;
Divaza: Oral administration.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Tablet for oral use. Two tablets per intake 3 times a day (approximately at the same time), outside of meal (between meals or 15 minutes before eating or drinking). The tablets should be held in mouth until completely dissolved.&#xD;
Placebo: Oral administration.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="65"/>
            <count group_id="B2" value="59"/>
            <count group_id="B3" value="124"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="65"/>
                    <count group_id="B2" value="59"/>
                    <count group_id="B3" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.4" spread="7.8"/>
                    <measurement group_id="B2" value="59.8" spread="7.4"/>
                    <measurement group_id="B3" value="60.7" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="65"/>
                    <count group_id="B2" value="59"/>
                    <count group_id="B3" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Russia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="65"/>
                    <count group_id="B2" value="59"/>
                    <count group_id="B3" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Mean Value of Lipoprotein Resistance to LPO.</title>
        <description>Based on laboratory evaluation. Change in the mean resistance of lipoprotein (LP) to lipid peroxidation (LPO) after 12-week therapy versus baseline.</description>
        <time_frame>12 weeks of the observation period.</time_frame>
        <population>1 patient in Divaza group had no laboratory data.</population>
        <group_list>
          <group group_id="O1">
            <title>Divaza</title>
            <description>Tablet for oral use. Two tablets per intake 3 times a day (approximately at the same time), outside of meal (between meals or 15 minutes before eating or drinking). The tablets should be held in mouth until completely dissolved.&#xD;
Divaza: Oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Tablet for oral use. Two tablets per intake 3 times a day (approximately at the same time), outside of meal (between meals or 15 minutes before eating or drinking). The tablets should be held in mouth until completely dissolved.&#xD;
Placebo: Oral administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Value of Lipoprotein Resistance to LPO.</title>
          <description>Based on laboratory evaluation. Change in the mean resistance of lipoprotein (LP) to lipid peroxidation (LPO) after 12-week therapy versus baseline.</description>
          <population>1 patient in Divaza group had no laboratory data.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Resistance of LP to LPO at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.4" spread="13.1"/>
                    <measurement group_id="O2" value="42.9" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resistance of LP to LPO after 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6" spread="12.5"/>
                    <measurement group_id="O2" value="49.4" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>∆ between baseline and after 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" spread="14.7"/>
                    <measurement group_id="O2" value="6.4" spread="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis applies to ∆ between baseline and after 12 weeks row.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>A priori threshold for statistical significance is split evenly between primary and secondary endpoints. α=0.025.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Improved Cognitive Function.</title>
        <description>MoCA (Montreal Cognitive Assessment) score +1 and over after 12-week therapy versus baseline. Minimum score is 0, maximum score is 30. Higher values represent a better outcome.</description>
        <time_frame>12 weeks of the observation period.</time_frame>
        <population>8 patients in Divaza group and 2 patients in Placebo group had no data for week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Divaza</title>
            <description>Tablet for oral use. Two tablets per intake 3 times a day (approximately at the same time), outside of meal (between meals or 15 minutes before eating or drinking). The tablets should be held in mouth until completely dissolved.&#xD;
Divaza: Oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Tablet for oral use. Two tablets per intake 3 times a day (approximately at the same time), outside of meal (between meals or 15 minutes before eating or drinking). The tablets should be held in mouth until completely dissolved.&#xD;
Placebo: Oral administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Improved Cognitive Function.</title>
          <description>MoCA (Montreal Cognitive Assessment) score +1 and over after 12-week therapy versus baseline. Minimum score is 0, maximum score is 30. Higher values represent a better outcome.</description>
          <population>8 patients in Divaza group and 2 patients in Placebo group had no data for week 12.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0272</p_value>
            <p_value_desc>A priori threshold for statistical significance is split evenly between primary and secondary endpoints. α=0.025.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Mean Level of Preformed LP Products (Mainly Lipid Hydroperoxides).</title>
        <description>Based on laboratory evaluation. Change in mean level of preformed LP products, predominantly lipid hydroperoxides after 12-week therapy versus baseline.&#xD;
The following kinetic parameters of chemiluminescence were measured: rapid chemiluminescence flare amplitude reflecting the stationary level of lipid hydroperoxides.</description>
        <time_frame>12 weeks of the observation period</time_frame>
        <population>1 patient in Divaza group had no laboratory data.</population>
        <group_list>
          <group group_id="O1">
            <title>Divaza</title>
            <description>Tablet for oral use. Two tablets per intake 3 times a day (approximately at the same time), outside of meal (between meals or 15 minutes before eating or drinking). The tablets should be held in mouth until completely dissolved.&#xD;
Divaza: Oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Tablet for oral use. Two tablets per intake 3 times a day (approximately at the same time), outside of meal (between meals or 15 minutes before eating or drinking). The tablets should be held in mouth until completely dissolved.&#xD;
Placebo: Oral administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Level of Preformed LP Products (Mainly Lipid Hydroperoxides).</title>
          <description>Based on laboratory evaluation. Change in mean level of preformed LP products, predominantly lipid hydroperoxides after 12-week therapy versus baseline.&#xD;
The following kinetic parameters of chemiluminescence were measured: rapid chemiluminescence flare amplitude reflecting the stationary level of lipid hydroperoxides.</description>
          <population>1 patient in Divaza group had no laboratory data.</population>
          <units>Mcmol / L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Level of preformed LPO products at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.5" spread="14.1"/>
                    <measurement group_id="O2" value="72.8" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Level of preformed LPO products after 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.7" spread="13.1"/>
                    <measurement group_id="O2" value="69.9" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>∆ between baseline and after 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="9.6"/>
                    <measurement group_id="O2" value="-2.9" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis applies to ∆ between baseline and after 12 weeks row.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8762</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Mean Value of Lipoprotein Ability for Oxidation.</title>
        <description>Based on laboratory evaluation. Change in mean value of lipoprotein ability for oxidation after 12-week therapy versus baseline.&#xD;
For plasma, draw blood into an EDTA tube and gently invert the tube 8 to 10 times to mix the anticoagulant. Centrifuge the tube, remove the stopper and draw off approximately 2/3 of the upper plasma layer into a labeled transfer tube using a transfer pipet bulb. Plasma must be separated from cells within 45 minutes of venipuncture. Measurement of oxidized LDL (oxLDL) has been incorporated into clinical practice in the diagnosis and treatment of lipid disorders (such as diabetes mellitus), atherosclerosis, and various liver and renal diseases, especially as it pertains to the evaluation of oxidative stress. Oxidized LDL-particles are considered to be an important driving factor in the pathophysiology of atherosclerosis and oxLDL measurement has been used to test the efficacy of CVD drugs (eg, statins) to reduce oxidative stress.</description>
        <time_frame>12 weeks of the observation period.</time_frame>
        <population>1 patient in Divaza group had no laboratory data.</population>
        <group_list>
          <group group_id="O1">
            <title>Divaza</title>
            <description>Tablet for oral use. Two tablets per intake 3 times a day (approximately at the same time), outside of meal (between meals or 15 minutes before eating or drinking). The tablets should be held in mouth until completely dissolved.&#xD;
Divaza: Oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Tablet for oral use. Two tablets per intake 3 times a day (approximately at the same time), outside of meal (between meals or 15 minutes before eating or drinking). The tablets should be held in mouth until completely dissolved.&#xD;
Placebo: Oral administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Value of Lipoprotein Ability for Oxidation.</title>
          <description>Based on laboratory evaluation. Change in mean value of lipoprotein ability for oxidation after 12-week therapy versus baseline.&#xD;
For plasma, draw blood into an EDTA tube and gently invert the tube 8 to 10 times to mix the anticoagulant. Centrifuge the tube, remove the stopper and draw off approximately 2/3 of the upper plasma layer into a labeled transfer tube using a transfer pipet bulb. Plasma must be separated from cells within 45 minutes of venipuncture. Measurement of oxidized LDL (oxLDL) has been incorporated into clinical practice in the diagnosis and treatment of lipid disorders (such as diabetes mellitus), atherosclerosis, and various liver and renal diseases, especially as it pertains to the evaluation of oxidative stress. Oxidized LDL-particles are considered to be an important driving factor in the pathophysiology of atherosclerosis and oxLDL measurement has been used to test the efficacy of CVD drugs (eg, statins) to reduce oxidative stress.</description>
          <population>1 patient in Divaza group had no laboratory data.</population>
          <units>mV</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LP ability for oxidation at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1027.3" spread="204.7"/>
                    <measurement group_id="O2" value="993.8" spread="264.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LP ability for oxidation after 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1024.1" spread="226.7"/>
                    <measurement group_id="O2" value="1040.6" spread="217.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>∆ between baseline and after 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.1" spread="192.1"/>
                    <measurement group_id="O2" value="57.0" spread="241.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis applies to ∆ between baseline and after 12 weeks row.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2082</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Mean Value of NO Products Serum Concentration.</title>
        <description>Based on laboratory evaluation. Change in the mean concentration of nitrites and nitrates in serum after 12-week therapy versus baseline. Griess Reaction assay.&#xD;
In the Griess reaction, first reported by Johann Peter Griess in 1879 as a method of analysis of nitrite (NO2-), nitrite reacts under acidic conditions with sulfanilic acid (HO3SC6H4NH2) to form a diazonium cation (HO3SC6H4-Ntriple bondN+) which subsequently couples to the aromatic amine 1-naphthylamine (C10H7NH2) to produce a red-violet coloured (λmax ≈ 540 nm), water-soluble azo dye (HO3SC6H4-Ndouble bondN-C10H6NH2).</description>
        <time_frame>12 weeks of the observation period.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Divaza</title>
            <description>Tablet for oral use. Two tablets per intake 3 times a day (approximately at the same time), outside of meal (between meals or 15 minutes before eating or drinking). The tablets should be held in mouth until completely dissolved.&#xD;
Divaza: Oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Tablet for oral use. Two tablets per intake 3 times a day (approximately at the same time), outside of meal (between meals or 15 minutes before eating or drinking). The tablets should be held in mouth until completely dissolved.&#xD;
Placebo: Oral administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Value of NO Products Serum Concentration.</title>
          <description>Based on laboratory evaluation. Change in the mean concentration of nitrites and nitrates in serum after 12-week therapy versus baseline. Griess Reaction assay.&#xD;
In the Griess reaction, first reported by Johann Peter Griess in 1879 as a method of analysis of nitrite (NO2-), nitrite reacts under acidic conditions with sulfanilic acid (HO3SC6H4NH2) to form a diazonium cation (HO3SC6H4-Ntriple bondN+) which subsequently couples to the aromatic amine 1-naphthylamine (C10H7NH2) to produce a red-violet coloured (λmax ≈ 540 nm), water-soluble azo dye (HO3SC6H4-Ndouble bondN-C10H6NH2).</description>
          <units>μmol per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NO-3 level at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.3" spread="14.9"/>
                    <measurement group_id="O2" value="69.0" spread="28.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NO-3 level (after cuff test) at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.4" spread="16.5"/>
                    <measurement group_id="O2" value="79.1" spread="33.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NO-3 level after 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.7" spread="23.9"/>
                    <measurement group_id="O2" value="63.3" spread="36.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NO-3 level (after cuff test) after 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.0" spread="15.6"/>
                    <measurement group_id="O2" value="61.1" spread="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NO-2 level at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.9" spread="16.0"/>
                    <measurement group_id="O2" value="62.8" spread="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NO-2 level (after cuff test) at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8" spread="16.1"/>
                    <measurement group_id="O2" value="69.6" spread="32.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NO-2 level after 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.9" spread="22.2"/>
                    <measurement group_id="O2" value="52.5" spread="35.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NO-2 level (after cuff test) after 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.0" spread="14.5"/>
                    <measurement group_id="O2" value="51.0" spread="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NO level at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="2.3"/>
                    <measurement group_id="O2" value="6.3" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NO level (after cuff test) at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="1.8"/>
                    <measurement group_id="O2" value="9.5" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NO level after 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="3.9"/>
                    <measurement group_id="O2" value="10.7" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NO level (after cuff test) after 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="2.8"/>
                    <measurement group_id="O2" value="10.1" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis applies to NO-3 data.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0038</p_value>
            <p_value_desc>The p-value associated with &quot;treatment*visit&quot; interaction between Divaza and Placebo treatment groups. Model includes cuff test status, treatment, visit and treatment*visit interaction.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis applies to NO-2 data.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0018</p_value>
            <p_value_desc>The p-value associated with &quot;treatment*visit&quot; interaction between Divaza and Placebo treatment groups. Model includes cuff test status, treatment, visit and treatment*visit interaction.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis applies to NO data.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.46</p_value>
            <p_value_desc>The p-value associated with &quot;treatment*visit&quot; interaction between Divaza and Placebo treatment groups. Model includes cuff test status, treatment, visit and treatment*visit interaction.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Mean Value of Platelet Aggregation.</title>
        <description>Based on laboratory evaluation. Change in mean platelet aggregation after 12-week therapy versus baseline.</description>
        <time_frame>12 weeks of the observation period.</time_frame>
        <population>ADP-AP - platelet aggregation (PA) induced by adenosine diphosphate (ADP) ADR-AP - platelet aggregation (PA) induced by adrenaline (ADR)</population>
        <group_list>
          <group group_id="O1">
            <title>Divaza</title>
            <description>Tablet for oral use. Two tablets per intake 3 times a day (approximately at the same time), outside of meal (between meals or 15 minutes before eating or drinking). The tablets should be held in mouth until completely dissolved.&#xD;
Divaza: Oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Tablet for oral use. Two tablets per intake 3 times a day (approximately at the same time), outside of meal (between meals or 15 minutes before eating or drinking). The tablets should be held in mouth until completely dissolved.&#xD;
Placebo: Oral administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Value of Platelet Aggregation.</title>
          <description>Based on laboratory evaluation. Change in mean platelet aggregation after 12-week therapy versus baseline.</description>
          <population>ADP-AP - platelet aggregation (PA) induced by adenosine diphosphate (ADP) ADR-AP - platelet aggregation (PA) induced by adrenaline (ADR)</population>
          <units>percentage aggregation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ADP-PA at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.9" spread="13.8"/>
                    <measurement group_id="O2" value="44.6" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADP-PA (after cuff test) at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.0" spread="14.0"/>
                    <measurement group_id="O2" value="51.9" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADP-PA after 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.3" spread="12.5"/>
                    <measurement group_id="O2" value="46.3" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADP-PA (after cuff test) after 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.7" spread="14.6"/>
                    <measurement group_id="O2" value="52.5" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADR-PA at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.4" spread="12.2"/>
                    <measurement group_id="O2" value="47.8" spread="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADR-PA (after cuff test) at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.7" spread="13.3"/>
                    <measurement group_id="O2" value="53.1" spread="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADR-PA after 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.7" spread="11.8"/>
                    <measurement group_id="O2" value="51.4" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADR-PA (after cuff test) after 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.1" spread="8.6"/>
                    <measurement group_id="O2" value="57.4" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis applies to ADP-PA data.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.88</p_value>
            <p_value_desc>The p-value associated with &quot;treatment*visit&quot; interaction between Divaza and Placebo treatment groups. Model includes cuff test status, treatment, visit and treatment*visit interaction.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis applies to ADR-PA data.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.93</p_value>
            <p_value_desc>The p-value associated with &quot;treatment*visit&quot; interaction between Divaza and Placebo treatment groups. Model includes cuff test status, treatment, visit and treatment*visit interaction.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During the treatment period - 12 weeks (start after taking the first dose of the study drug, during the entire period of the study therapy and within 24 hours after the last dose of the study drug).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Divaza</title>
          <description>Tablet for oral use. Two tablets per intake 3 times a day (approximately at the same time), outside of meal (between meals or 15 minutes before eating or drinking). The tablets should be held in mouth until completely dissolved.&#xD;
Divaza: Oral administration.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Tablet for oral use. Two tablets per intake 3 times a day (approximately at the same time), outside of meal (between meals or 15 minutes before eating or drinking). The tablets should be held in mouth until completely dissolved.&#xD;
Placebo: Oral administration.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Odinophagy</sub_title>
                <description>Sore throat when swallowing</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <description>Tick bite</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Increased blood pressure</sub_title>
                <description>Increase in blood pressure to 235/120 mmHg</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nosebleed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mikhail Putilovskiy, MD, PhD, Clinical and Medical Department Director</name_or_title>
      <organization>MATERIA MEDICA HOLDING</organization>
      <phone>+74952761571 ext 302</phone>
      <email>PutilovskiyMA@materiamedica.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

